Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.45 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22587767 | 0.87 | SLC16A3 (0.54) | NPC1RAB9ASLC16A3NPSR1ASAH1 | |
| SCHEMBL24333316 | 0.87 | SLC16A3 (0.54) | NPC1RAB9ASLC16A3NPSR1PIM1 | |
| SCHEMBL24333587 | 0.86 | SLC16A3 (0.53) | NPC1RAB9ASLC16A3NPSR1ASAH1 | |
| SCHEMBL24333939 | 0.84 | SLC16A3 (0.70) | NPC1RAB9ASLC16A3ASAH1PIM1 | |
| SCHEMBL4505056 | 0.83 | SLC16A3 (0.75) | RAB9ASLC16A3MTHFD2KDM4EMAPT | |
| SCHEMBL30492814 | 0.82 | — | — | |
| SCHEMBL24333614 | 0.81 | SLC16A3 (0.45) | NPC1RAB9ASLC16A3NPSR1PIM1 | |
| SCHEMBL24333272 | 0.78 | SLC16A3 (0.43) | NPC1RAB9ASLC16A3PIM1CSNK2A2 | |
| SCHEMBL23010836 | 0.78 | HTR3A (0.54) | NPC1RAB9ASLC16A3HTR3AKDM4E | |
| SCHEMBL20341763 | 0.78 | NPC1 (0.53) | NPC1RAB9ANPSR1MAPTHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074902-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) | 2025-03-06 | — | — | US | disclosed |
| WO-2025002040-A1 | CRYSTAL FORM OR SALT OF BICYCLIC HETEROARYL AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海京新生物医药有限公司 | 2025-01-02 | — | — | WO | disclosed |
| EP-4458824-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | Shanghai Jingxin Biomedical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118488951-A | Fused bicyclic heteroaryl amide compounds as inhibitors of protein aggregation | 上海京新生物医药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023125376-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | 上海京新生物医药有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125376-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | 上海京新生物医药有限公司 | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074902-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | HTT, PARK7, FUS | NPC1 1857/4885RAB9A 1116/4885SLC16A3 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.